650,000 people have chemotherapy annually. The est
Post# of 72440
Let's say that 1/4 of them are at risk of oral mucositis. (The real figure is probably much higher). So let's say about 300,000 people a year need Brilacidin-OM.
Anyone really think that a potential patient population of 300k or more would really warrant a mere 15 million bucks for a deal for a drug that prevents a severe side effect like oral mucositis?
Me neither.